Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray

Core Insights - Kane Biotech Inc. has successfully enrolled 28 participants in its revyve Antimicrobial Wound Gel and Spray U.S. Case Series Studies, surpassing the initial target of 25 participants [1] - The company’s products, including the revyve Antimicrobial Wound Gel and Spray, have received U.S. FDA 510(k) clearance, indicating regulatory approval for their use [3][4] - Data from the clinical series is expected to be presented at various medical meetings in 2025 and 2026, highlighting the growing interest from clinicians and patients [4] Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which are significant contributors to antibiotic resistance in wounds [4] - The company aims to improve healing outcomes for patients suffering from challenging wounds and burns through its revyve product line [4] - The revyve products are designed to address both biofilms and wound bacteria, potentially transforming the treatment landscape for wound care [4]